Larvol Delta - Cardiff-Oncology-Announces-Presentation-of-Positive-Results-from-its-Randomized-Controlled-Phase-2-Trial-of-Onvansertib-in-FirstLine-RASMutated-mCRC-at-the-2026-ASCO-Annual-Meeting

onvansertib (PCM-075) - Cardiff Oncology

https://www.globenewswire.com/news-release/2026/06/02/3305287/0/en/cardiff-oncology-announces-presentation-of-positive-results-from-its-randomized-controlled-phase-2-trial-of-onvansertib-in-first-line-ras-mutated-mcrc-at-the-2026-asco-annual-meeti.html

Jun 2, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next